Compare JD.Com Inc (JD) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

JD.com trades at $26.78, up 0.22% on the day, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $0.93 surpassing the $0.86 forecast. Revenue for 2025 reached $1.31 trillion, though net income margin compressed to 1.13%. The company is pursuing growth via acquisitions, such as the pending $2.5 billion Ceconomy deal, which recently gained EU approval momentum (Reuters, 2026-10-02).

The stock appears undervalued with a P/E of 17.78 and P/S of 0.2, well below sector averages. Analyst consensus is strongly bullish with a $35.38 price target, implying ~32% upside. Key risks include regulatory scrutiny in China and Europe, volatile cash flows, and competitive pressures. The robust balance sheet with $234 billion cash provides a margin of safety, but investors must weigh growth initiatives against macroeconomic headwinds.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.